BioChem, Biovector Therapeutics SA deal

BCHXF’s IAF BioVac Inc. subsidiary (Laval, Quebec) and Biovector will develop nasally administered vaccines for influenza, Neisseria meningitidis and streptococcus

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE